Member news

The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation committed to the advancement of cell and gene therapies has released its Good Manufacturing Practice (GMP) Report 2024.

PIR International recently partnered with Closed Loop Medicine in appointing Luba Greenwood as Non-Executive Chair

Further strengthens Poolbeg's robust intellectual property portfolio

SP Angel, a small London based investment bank, have recently publish a reseach note on Ananda.

Quotient Sciences announced the installation of Centillion’s™ proprietary Biofoundry-in-a-Box (BiaB™), a modular, integrated, and automated RNA-micro factory which enables the end-to-end production of various RNA-based products.

Cushman & Wakefield's Locating Science life sciences report wins top award from the Society of Property Researchers

OMass Therapeutics, a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Professor Steven Charlton as Chief Scientific Officer (CSO).

Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation technology that controls T cells to guide the immune system, has appointed Darlene Deptula-Hicks as Chief Financial Officer.

We were delighted to welcome over 100 guests to International Men’s Day at Stevenage Bioscience Catalyst. As part of our series of diversity and inclusion events this year, which have included International Women’s Day and PRIDE, we hosted talks, a Q&A and a wellbeing workshop to promote gender inclusivity, equality and allyship at SBC.

Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies designed to be safe, convenient, and precisely targeted, today announces it has established a UK subsidiary, based on the Oxford Science Park, as the company continues its development into an international leader in food allergies.

Microbiotica announces that the first patient has been dosed in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients.

CN Bio, a leading provider of Organ-on-a-chip Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® Bioavailability assay kit: Human 18.

Degree apprentice with AstraZeneca, Emily Butterworth, becomes the first Manchester Met apprentice to be highly commended in the Royal Society of Biology’s Apprentice of the Year Awards 2024.

Scancell announces strengthening of leadership team as it closes on value-generating inflection points

The Rosalind Franklin Institute has appointed four new trustees: Malcolm Skingle, Hilary Newiss, Bruce Pritchard and Caroline Carter.

MultiOmic Health, a leading AI-enabled drug discovery company, announces the identification of novel patient endotypes and the development of proprietary biomarkers for stratifying diabetic kidney disease (DKD) patients.

Facility dedicated to cryopreservation of leukapheresis starting materials to support clinical and commercial cell-based therapy programs

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with IMU Biosciences and is pleased to announce the placements of Dr John Baker as Chief Executive Officer and Dr Jason Brown as Chief Business Officer.

Babraham Research Campus Ltd, which is responsible for the development and management of Babraham Research Campus is delighted to announce the appointment of Dr Louise Jopling to the newly created role of Chief Scientific & Innovation Officer.

AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy); Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL